BACKGROUND:Beta-Carotene supplementation showed neither benefit nor harm among apparently healthy physicians (all men) in the Physicians' Health Study (PHS) trial. The objective of the current investigation was to evaluate how long-term beta-carotene supplementation affects molecular markers of lung carcinogenesis in the PHS. METHODS: The protein levels of total p53, cyclin D1, proliferating cellular nuclear antigen (PCNA), retinoic acid receptor beta (RARbeta), and cytochrome p450enzyme 1A1 (CYP1A1) were measured using the immunohistochemical method in 40 available archival lung tissue samples from patients who were diagnosed with lung cancer in the PHS. The protein levels of these markers were compared by category of beta-carotene treatment assignment and other characteristics using unconditional logistic regression models. RESULTS: The positivity for total p53, RARbeta, cyclin D1, and PCNA was nonsignificantly lower among lung cancer patients who were assigned to receive beta-carotene than those who were assigned to receive beta-carotene placebo. There was a borderline significant difference in CYP1A1 positivity with an OR of 0.2 (95% confidence interval, 0.2-1.1; P = .06) in a comparison of men who received beta-carotene and men who received beta-carotene placebo. CONCLUSIONS: The 50-mg beta-carotene supplementation on alternate days had no significant influence on molecular markers of lung carcinogenesis that were evaluated in the PHS. This finding provides mechanistic support for the main PHS trial results of beta-carotene, which demonstrated no benefit or harm to the risk of developing lung cancer. (c) 2009 American Cancer Society.
RCT Entities:
BACKGROUND:Beta-Carotene supplementation showed neither benefit nor harm among apparently healthy physicians (all men) in the Physicians' Health Study (PHS) trial. The objective of the current investigation was to evaluate how long-term beta-carotene supplementation affects molecular markers of lung carcinogenesis in the PHS. METHODS: The protein levels of total p53, cyclin D1, proliferating cellular nuclear antigen (PCNA), retinoic acid receptor beta (RARbeta), and cytochrome p450 enzyme 1A1 (CYP1A1) were measured using the immunohistochemical method in 40 available archival lung tissue samples from patients who were diagnosed with lung cancer in the PHS. The protein levels of these markers were compared by category of beta-carotene treatment assignment and other characteristics using unconditional logistic regression models. RESULTS: The positivity for total p53, RARbeta, cyclin D1, and PCNA was nonsignificantly lower among lung cancerpatients who were assigned to receive beta-carotene than those who were assigned to receive beta-carotene placebo. There was a borderline significant difference in CYP1A1 positivity with an OR of 0.2 (95% confidence interval, 0.2-1.1; P = .06) in a comparison of men who received beta-carotene and men who received beta-carotene placebo. CONCLUSIONS: The 50-mg beta-carotene supplementation on alternate days had no significant influence on molecular markers of lung carcinogenesis that were evaluated in the PHS. This finding provides mechanistic support for the main PHS trial results of beta-carotene, which demonstrated no benefit or harm to the risk of developing lung cancer. (c) 2009 American Cancer Society.
Authors: Margaret E Wright; Susan T Mayne; Christine A Swanson; Rashmi Sinha; Michael C R Alavanja Journal: Cancer Causes Control Date: 2003-02 Impact factor: 2.506
Authors: X C Xu; G Sozzi; J S Lee; J J Lee; U Pastorino; S Pilotti; J M Kurie; W K Hong; R Lotan Journal: J Natl Cancer Inst Date: 1997-05-07 Impact factor: 13.506
Authors: F R Khuri; R Lotan; B L Kemp; S M Lippman; H Wu; L Feng; J J Lee; C S Cooksley; B Parr; E Chang; G L Walsh; J S Lee; W K Hong; X C Xu Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: M Paolini; A Antelli; L Pozzetti; D Spetlova; P Perocco; L Valgimigli; G F Pedulli; G Cantelli-Forti Journal: Carcinogenesis Date: 2001-09 Impact factor: 4.944
Authors: Yoon Soo Chang; Jae Ho Chung; Dong Hwan Shin; Kyung Young Chung; Young Sam Kim; Joon Chang; Sung Kyu Kim; Se Kyu Kim Journal: Yonsei Med J Date: 2004-06-30 Impact factor: 2.759
Authors: Jonathan M Kurie; Reuben Lotan; J Jack Lee; Jin Soo Lee; Rodolfo C Morice; Diane D Liu; Xiao-Chun Xu; Fadlo R Khuri; Jae Y Ro; Walter N Hittelman; Garrett L Walsh; Jack A Roth; John D Minna; Waun Ki Hong Journal: J Natl Cancer Inst Date: 2003-02-05 Impact factor: 13.506
Authors: Koichi Aizawa; Chun Liu; Sudipta Veeramachaneni; Kang-Quan Hu; Donald E Smith; Xiang-Dong Wang Journal: Lung Cancer Date: 2013-12 Impact factor: 5.705
Authors: Margaret E Wright; Steve D Groshong; Kirsti Husgafvel-Pursiainen; Erin Genova; M Scott Lucia; Henrik Wolff; Jarmo Virtamo; Demetrius Albanes Journal: Cancer Prev Res (Phila) Date: 2010-05-18